Δ **The Delta Consortium**
Regulatory Consulting, Ltd.

10 Packer Avenue
Rumson, NJ 07760

Curriculum Vitae

David M. Petrick, VMD, JD
President

Education:

BA - Kutztown State College (now Kutztown University)
Liberal Arts – Natural Sciences
May, 1971

VMD - University of Pennsylvania
School of Veterinary Medicine
Veterinary medical degree
May, 1976

JD - Seton Hall University
School of Law
Law degree
May, 1999

Professional Work Experience:

June, 1976 – September, 1979

Served in the United States Air Force as a Base Veterinarian, at Rickenbacher AFB, Columbus, Ohio. In this position, I managed the Base Veterinary Office, was the prime food and food facility inspector on the base, was a member of the base Aerospace Medicine Committee and served on the Base Hospital Commander's Staff.

September, 1979 – September, 1989

Employed by American Cyanamid Company, Agricultural Research Division, in the Animal Drug Development Department. During this time, I assumed positions of greater responsibility as my career progressed.

Regulatory Affairs Coordinator – joined the company in the Regulatory group and worked on various products including feed antibiotics, animal pharmaceuticals, and serviced the state registration area.

Program Manager – promoted to a position in research development and designed and ran research programs to obtain approval for animal drug products in the US. During this period, I had responsibility for chlortetracycline containing products for food animals, for the levamisole line of products in food animals, and for the companion animals products in the Cyanamid line.

Manager, Regulatory Affairs – promoted to a position to manage the Regulatory group for the Research Department. This entailed the establishment of all regulatory strategies for products in development for the US and for ensuring compliance with FDA standards for products already approved. The position also coordinated the regulatory strategies of the US with the International markets. During this time, Cyanamid received multiple approvals for food animal products including a new anticoccidial for poultry, a feed through larvacide for cattle (an EPA approval), and a new anthelmintic presentation of levamisole.

Special Projects

Cyanamid encouraged my participation in the Animal Health Institute (AHI), the trade association of the animal health products industry in the US. During this time, I was selected to serve as chair of the Animal Drug Section, the main regulatory body for the association. I also served as chair of the International Section of AHI, the group which acted as a US liaison with European animal health trade associations. I was the chair of the Animal Welfare Committee, a standing committee established to address industry issues related to the animal rights movement.

Through the AHI, I participated in all the major issues facing the industry. I was an active participant, serving as a company and industry spokesperson for the subtherapeutic use of antibiotics in animals. I also actively participated in the debate that led to the creation of generic animal drugs and created patent term restoration for pioneer companies. I served as a company and industry spokesperson for the public debate over the approval and use of bovine somatotropin (BST), which led to multiple public meetings and to testimony before the US Congress on the potential impact on the use of BST to the dairy industry.

September, 1989 – June, 2004

Employed by Schering-Plough Animal Health (SPAH) as Director, Worldwide Regulatory Affairs. I was hired to head and develop the

Regulatory Affairs group in the Animal Health Research Division. During this time, my responsibilities expanded as the business and the organization did. The group transitioned from an organization of 9 professionals to 32 professionals during my tenure. The position, when I left, had responsibility for the global management of all animal health products, including animal drugs, animal biologicals, and animal pesticide products. I had direct responsibility to deal with the US Center for Veterinary Medicine of the FDA, the Center for Veterinary Biologicals of the USDA, and the US EPA; as well as the Committee for Veterinary Medicinal Products in the EU and the EMA. I also had a consulting responsibility for product approvals in all other countries around the world. In addition to the regulatory affairs responsibilities, Regulatory Compliance also reported to me. I was promoted during my tenure, with increasing responsibilities, to the position of Senior Director, Worldwide Regulatory Affairs and Regulatory Compliance.

During this time, approval was granted for florfenicol, currently the largest selling product in the line. Also during this time, a canine otitis externa product, which became the market leader, was approved. In addition, a novel product to treat dry eye in dogs was approved; a new floroquinolone for dogs and cats was approved; and an entire line of products for aquaculture was developed and approved, including an antibiotic and an anthelmintic to treat sea lice in salmon.

Special Projects

Again via AHI, I participated in the public debate over antibiotic use and resistance development in animals during this time. I was the company representative on the various groups formed by the AHI to address the various issues surrounding the debate. I also played a role in the discussion that eventually led to the creation of User Fees at FDA for animal drug review and approval.

Within the company, SPAH acquired Mallinckrodt Animal Health, a company approximately twice its size. I served on the Acquisition Team and then the Transition Team for SPAH, defining the needs for Regulatory Affairs in the new organization. With this purchase, SPAH moved to a truly global animal health company, and the regulatory department had its largest expansion in personnel.

I completed law school during my time at Schering, all the while running the Regulatory Affairs Department. It was during my time in law school that Schering-Plough Animal Health made the Mallinckrodt acquisition.

July, 2004 – Present

I am an independent consultant in the field of regulatory affairs. I established my own company (The Delta Consortium Regulatory Consulting, Limited) to provide consulting regulatory expertise to companies and individuals who are working toward the development, testing, submission, and approval of products for the animal health business.

I give lectures on the US Regulatory Process for animal drugs, biologicals and pesticides in the US and in various European venues. This is carried out with industry training companies and directly for clients.

I serve as the regulatory consultant for The Veterinary Consultancy, a consulting company specializing in US animal health products.

I serve as the Regulatory Director for Triveritas USA, a consulting company for animal health products.

I served as the Executive Vice President Research, Development, and Regulatory Affairs for Velcera, Inc., a venture capital funded veterinary products company based in the US. The company was successfully sold in 2013.

Professional Associations

American Veterinary Medical Association
American Bar Association
New Jersey Bar Association
Member, New Jersey Bar